E
Emalex Biosciences
A biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions
About Emalex Biosciences
Emalex Biosciences is a biopharmaceutical startup that focuses on developing new treatments for central nervous system disorders, particularly Tourette Syndrome (TS) and childhood-onset fluency disorder, commonly known as stuttering. The company operates in the healthcare market, specifically within the pharmaceutical sector.
Read full description
Emalex's primary clients are patients suffering from these disorders, who currently have limited treatment options. The company is currently in the late stages of clinical trials for a new class of drug aimed at providing relief for TS patients. This drug, Ecopipam, is being tested in a Phase 3 trial, which is typically the final stage before a drug is considered for approval by regulatory bodies like the U.S. Food and Drug Administration (FDA).
The company's business model revolves around the research, development, and eventual commercialization of these new treatments. Once approved, Emalex will generate revenue through the sale of these drugs to healthcare providers and patients.
Emalex Biosciences is committed to improving the lives of people living with TS and stuttering, not only by addressing the physical symptoms but also the social stigma and emotional distress associated with these disorders.
At a glance
- Status
- Acquired
- Founded
- 2018
- Headquarters
- Chicago, United States
- Employees
- 54
- Open positions
- None listed
- Dealroom signal
- 58.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Emalex Biosciences.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Apr 2026 | $700M | $700M | Teva | ↗ |
| SERIES DOther financing | Nov 2022 | $250M | $1B | Valor Equity Partners · Paragon Biosciences · Bain Capital Life Sciences · Fidelity Investments | ↗ |
Growth signals
Latest recorded traffic for Emalex Biosciences is 890 monthly website visits, down 55.5% over the last three months. Emalex Biosciences's team grew 17.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later5 investors entered at this stage
Horizon Technology Finance Corporation
Paragon Biosciences
Fidelity Investments
Valor Equity Partners
Bain Capital Life Sciences
Other known investors1 additional known investor
Teva
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Emalex Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Emalex Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.